The label for Adalimumab was revised on 2026-07-08 to include a boxed warning. This significant update from the FDA highlights an increased risk of serious infections and malignancy associated with the drug.
Background
Adalimumab is a well-established biologic medication, widely prescribed for various autoimmune and inflammatory conditions. It is known under numerous brand names and biosimilars, including Humira, Hulio, Yusimry, Yuflyma, Idacio, Simlandi, Amjevita, Cyltezo, Hadlima, and Hyrimoz. As a tumor necrosis factor (TNF) inhibitor, it works by blocking TNF-alpha, a protein involved in inflammation. Boxed warnings, often referred to as black box warnings, represent the highest level of safety alert mandated by the FDA for prescription drugs. They are used when there is significant evidence of a serious hazard associated with the drug, requiring healthcare professionals and patients to be fully informed of these risks.
What this means
The implementation of a boxed warning on the Adalimumab label signals a heightened emphasis on critical safety considerations for both healthcare providers and patients. This warning specifically highlights the increased potential for serious infections, which may necessitate hospitalization, and the risk of developing malignancies. For clinicians, this means a reinforced need for thorough patient screening before initiating Adalimumab therapy, ongoing monitoring for signs of infection or malignancy during treatment, and careful consideration of the risk-benefit profile for each individual patient. Patients currently using or considering Adalimumab should be fully informed about these potential serious adverse effects. Open discussions with their healthcare providers are crucial to understand the implications of this warning, recognize symptoms that require immediate medical attention, and ensure informed decision-making regarding their treatment plan.
Source
This label revision was issued by the FDA on 2026-07-08. The full prescribing information, including the complete boxed warning, is available on the dailymed.nlm.nih.gov website.